AstraZeneca's Zactima to Earn Almost Five Percent Patient Share in the Treatment of Non-Small-Cell Lung Cancer By 2016
Posted on: Thursday, 20 March 2008, 09:01 CDT
WALTHAM, Mass., March 20 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that the emerging drug Zactima from AstraZeneca will earn 4.7 percent patient share in the treatment of non-small-cell lung cancer (NSCLC) by 2016. Surveyed oncologists indicate that they would prescribe Zactima to 30 percent of their patients with advanced non-small-cell lung cancer. Also, 38 percent of the physicians surveyed indicate they will use Zactima as an adjunct to current therapy rather than as a replacement. Zactima is forecasted to launch in 2008 in the United States and Europe and in 2010 in Japan.
According to the new report entitled Non-Small-Cell Lung Cancer (Advanced): Current Gold-Standard Therapy Continues to Be Most Efficacious; physicians indicate that the most promising emerging therapies for the treatment of non-small-cell lung cancer will not match the current gold- standard regimen comprising Roche/Genentech/Chugai's Avastin, Bristol-Myers Squibb's Taxol, and Bristol-Myers Squibb's Paraplatin.
"Although some therapies in development for advanced NSCLC hold promise, most have efficacy, safety and tolerability, and/or delivery features that merit inferior scores compared with the Avastin/Taxol/Paraplatin regimen," said Andrew Merron, Ph.D., analyst at Decision Resources. "A therapy's effect on overall survival is the attribute that most influences prescribing decisions in advanced non-small-cell lung cancer. Data and the opinions of interviewed thought leaders indicate that Avastin/Taxol/Paraplatin has advantages over the sales-leading combination of Sanofi-Aventis's Taxotere and Bristol-Myers Squibb's Platinol-AQ on overall survival."
About the Report
Non-Small-Cell Lung Cancer (Advanced): Current Gold-Standard Therapy Continues to Be Most Efficacious is a DecisionBase 2008 report from Decision Resources. DecisionBase 2008 combines market forecasts with clinical and commercial end points to assess market share projections in 35 indications. These outputs are driven by quantitative and qualitative primary research. DecisionBase 2008 provides detailed market share, patient share, and price- per-day projections for emerging drugs in development. The market share projections are based on prescriber surveys that compare physicians' expectations of a potential target product profile with an emerging product profile of the leading drugs in development.
The report can be purchased by contacting Decision Resources. Members of the media may request an interview with an analyst.
About Decision Resources
Decision Resources, Inc. (http://www.decisionresources.com/) is a world leader in market research publications, advisory services, and consulting designed to help clients shape strategy, allocate resources, and master their chosen markets. Decision Resources is a Decision Resources, Inc. company.
All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.
For more information, contact: Elizabeth Marshall Decision Resources, Inc. 781-296-2563 emarshall@dresources.com
Decision Resources, Inc.
CONTACT: Elizabeth Marshall of Decision Resources, Inc.,+1-781-296-2563, emarshall@dresources.com
Web site: http://www.decisionresources.com/
Source: PRNewswire
Related Articles
- Amrubicin Receives FDA Fast Track Designation for the Treatment of Small Cell Lung Cancer After First-Line Chemotherapy
- Data From Studies of Amrubicin in Small-Cell Lung Cancer Presented at the 2008 American Society of Clinical Oncology Meeting Demonstrate Single Agent Anti-Tumor Activity in Western Patient Population
- Amrubicin is Designated As an Orphan Medicinal Product By the European Commission for the Treatment of Small Cell Lung Cancer
- Amrubicin(R) Receives FDA Orphan Drug Designation for the Treatment of Small Cell Lung Cancer
- Pharmion's Amrubicin Shows Encouraging Results Compared to Standard of Care in Second Line Treatment of Small Cell Lung Cancer
- Pharmion Initiates Pivotal Phase 3 Study of Amrubicin in Small Cell Lung Cancer
- Pharmion's Amrubicin Shows Encouraging Results Compared to Standard of Care in Second Line Treatment of Small Cell Lung Cancer
- Sunesis Pharmaceuticals Initiates Phase II Clinical Trial of SNS-595 in Small Cell Lung Cancer
- NeoRx Announces Treatment of First Patient With Picoplatin in Phase 2 Clinical Trial in Small Cell Lung Cancer
- Point Therapeutics Achieves Interim Tumor Response Criteria in Phase 2 Non-Small Cell Lung Cancer Study; Company Advances Talabostat to Second Stage of Study
User Comments (0)
RSS Feeds